Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

5.240 +0.090 (+1.75%)
Streaming Delayed Price Updated: 10:51 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 4 5 Next >
Analyst Expectations for Nuvation Bio's Future
 
Via Benzinga
Where Nuvation Bio Stands With Analysts
 
Via Benzinga
The 7 Worst Stocks to Buy Now
With the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now. 
Via InvestorPlace
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program
 
Via Benzinga
Short Volatility Alert: Nuvation Bio Inc.
On Friday, shares of Nuvation Bio Inc. (NYSE: NUVB) experienced volatile short activity. After the activity, the stock price went up +0% to $4.04. The overall sentiment for NUVB has been Bearish. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
 
Via Benzinga
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
Netflix Price Target Cut By This Analyst, Plus Morgan Stanley Predicts $403 For McKesson
UBS cut the price target for Coupa Software Incorporated (NASDAQ: COUP) from $84 to $76. Coupa Software shares fell 4.9% to $64.44 in pre-market trading. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 51 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 92 companies set new 52-week lows. 
Via Benzinga
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
From Nuvation Bio Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 100 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 61 companies made new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million. 
Via Benzinga
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
From Nuvation Bio Inc.
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
From Nuvation Bio Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.